Heterologous targeting peptide grafted AAVS
AssigneeUniversity of Massachusetts
InventorsMiguel Sena Esteves, Sourav Roy Choudhury
Life of this patent
Estimating the term…
Abstract
The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
Claims18
An adeno associated virus capsid protein comprising an N-terminally grafted heterologous targeting peptide, wherein:
- (i) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype;
- and
- (ii) the targeting peptide is a CNS-targeting polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:
- 5, that is inserted between the first and second amino acid residues of the VP2 capsid protein.
An adeno associated virus capsid protein comprising an N-terminally grafted heterologous targeting peptide, wherein:
- (i) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype;
- and
- (ii) the targeting peptide is a CNS-targeting polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:
- 7, that is inserted between the first and second amino acid residues of the VP2 capsid protein.
An adeno associated virus capsid protein comprising an N-terminally grafted heterologous targeting peptide, wherein:
- (i) the capsid protein is a VP2 capsid protein that is not of an AAV2 serotype;
- and
- (ii) the targeting peptide is a CNS-targeting polypeptide encoded by a nucleic acid consisting of the nucleotide sequence set forth in SEQ ID NO:
- 29, that is inserted between the first and second amino acid residues of the VP2 capsid protein.
Dependencies are inferred from the claim text.